Translational medicine: Primed for resistance

Nature

Volumn 483, Issue 7387, 2012, Pages 44-45

  Solit, David B ^a   Jänne, Pasi A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; VEMURAFENIB;

CANCER; CELL ORGANELLE; DISEASE TREATMENT; DRUG; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC ANALYSIS; IDENTIFICATION METHOD; MEDICINE;

CANCER CELL; CANCER RESISTANCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL DIVISION; COLORECTAL CANCER; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; HUMAN; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEEDBACK, PHYSIOLOGICAL; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84857740115     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/483044a     Document Type: Short Survey

References (12)

1. Chapman, P. B. et al. N. Engl. J. Med. 364, 2507-2516 (2011).
2. Kopetz, S. et al. J. Clin. Oncol. 28 (ASCO Meet. Abstr. Pt 1), abstr. 3534 (2010).
3. Prahallad, A. et al. Nature 483, 100-103 (2012).
4. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. Nature 464, 427-430 (2010).
5. Nazarian, R. et al. Nature 468, 973-977 (2010).
6. Poulikakos, P. I. et al. Nature 480, 387-390 (2011).
7. Corcoran, R. B. et al. Cancer Discov. http://dx.doi.org/10.1158/2159- 8290. CD-11-0341 (2012).
8. Di Nicolantonio, F. et al. J. Clin. Oncol. 26, 5705-5712 (2008).
9. Joseph, E. W. et al. Proc. Natl Acad. Sci. USA 107, 14903-14908 (2010).
10. Oberholzer, P. A. et al. J. Clin. Oncol. 30, 316-321 (2012).
11. Su, F. et al. N. Engl. J. Med. 366, 207-215 (2012).
12. Infante, J. R. et al. J. Clin. Oncol. 29 (ASCO Meet. Abstr. Pt 1), abstr. CRA8503 (2011).